Leniolisib is a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). This category contains Leniolisib reference standards… Read more
Leniolisib is a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). This category contains Leniolisib reference standards along with critical related compounds, such as the N-nitroso impurity, which are essential for comprehensive impurity profiling. Pharmaceutical laboratories rely on these high-quality materials to conduct rigorous quality control and stability testing, ensuring compliance with regulatory requirements. The inclusion of stable isotope labelled compounds facilitates accurate quantification during bioanalytical method validation and pharmacokinetic studies, providing the precision needed to track drug behavior within complex matrices. By utilizing these characterized standards, researchers can effectively identify, isolate, and monitor both the parent drug and its degradation products, ultimately supporting the development and safety assessment of therapeutic interventions targeting PI3Kδ signaling pathways.